Literature DB >> 29201877

Eravacycline for treatment of complicated intra-abdominal infections: the fire is not ignited!

Patrick M Honore1, Herbert D Spapen1.   

Abstract

Entities:  

Year:  2017        PMID： 29201877      PMCID： PMC5690972          DOI： 10.21037/atm.2017.08.15

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  14 in total

1.  Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms.

Authors:  Marguerite L Monogue; Abrar K Thabit; Yukihiro Hamada; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 2.  Continuous renal replacement therapy-related strategies to avoid colistin toxicity: a clinically orientated review.

Authors:  Patrick M Honoré; Rita Jacobs; Olivier Joannes-Boyau; Stijn Lochy; Willem Boer; Elisabeth De Waele; Viola Van Gorp; Jouke De Regt; Vincent Collin; Herbert D Spapen
Journal:  Blood Purif       Date:  2014-07-30       Impact factor: 2.614

Review 3.  The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?

Authors:  Matthew E Falagas; Andreas D Mavroudis; Konstantinos Z Vardakas
Journal:  Expert Rev Anti Infect Ther       Date:  2016-08       Impact factor: 5.091

Review 4.  Multidrug-resistant Gram-negative bacteria: a product of globalization.

Authors:  P M Hawkey
Journal:  J Hosp Infect       Date:  2015-02-04       Impact factor: 3.926

Review 5.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

6.  In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii.

Authors:  David M Livermore; Shazad Mushtaq; Marina Warner; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

Review 7.  Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae.

Authors:  Joshua T Thaden; Jason M Pogue; Keith S Kaye
Journal:  Virulence       Date:  2016-07-06       Impact factor: 5.882

8.  Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).

Authors:  Joseph Solomkin; Ellie Hershberger; Benjamin Miller; Myra Popejoy; Ian Friedland; Judith Steenbergen; Minjung Yoon; Sylva Collins; Guojun Yuan; Philip S Barie; Christian Eckmann
Journal:  Clin Infect Dis       Date:  2015-02-10       Impact factor: 9.079

9.  Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.

Authors:  John E Mazuski; Leanne B Gasink; Jon Armstrong; Helen Broadhurst; Greg G Stone; Douglas Rank; Lily Llorens; Paul Newell; Jan Pachl
Journal:  Clin Infect Dis       Date:  2016-03-08       Impact factor: 9.079

10.  Assessing the risk: Scoring systems for outcome prediction in emergency laparotomies.

Authors:  Deb Sanjay Nag
Journal:  Biomedicine (Taipei)       Date:  2015-11-28
View more
  1 in total

Review 1.  Eravacycline, a newly approved fluorocycline.

Authors:  Young Ran Lee; Caitlin Elizabeth Burton
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-06-07       Impact factor: 3.267
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.